FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1652253116> ?p ?o ?g. }

• W1652253116 endingPage "1581" @default.
• W1652253116 startingPage "1581" @default.
• W1652253116 abstract "The effects of sorafenib for Chinese patients with metastatic renal cell cancer (mRCC) were evaluated to figure out the relationship between clinical variables and prognosis. The data were analyzed retrospectively from six comprehensive cancer centers in Northeast China. All cases were diagnosed as mRCC histopathologically without exception. Patients were taken 400 mg sorafenib orally twice daily until progression of disease or intolerable toxic reaction occurred. Overall survival (OS), progression-free survival (PFS), and the influence of clinical variables on survival were appointed as main outcome measures. Clinical data were analyzed using SPSS statistical software. P<0.05 was considered as statistically significant. A total of 131 patients were available for survival analysis. The median follow-up periods were 16.9 months, and the median OS and PFS were 16.1 months and 10.5 months, respectively. Univariate analysis showed that Eastern Cooperative Oncology Group performance status (ECOG PS), metastatic sites, and previous therapy were significantly associated with OS, whereas PFS was merely associated with ECOG PS and previous therapy. The multivariate analysis suggested that ECOG PS, metastatic sites, and previous therapy were the independent prognostic factors for OS, and ECOG PS and previous therapy as the independent prognostic factors for PFS. In the subgroup analysis for patients with visceral metastasis, the prognosis of patients with lung metastasis alone was better than those cases with liver metastasis alone or multiple organs metastasis. In our study, sorafenib shows a higher curative activity for patients with mRCC in Northeast China. ECOG PS, metastatic lesions, and previous therapy may be important parameters for OS and PFS prediction. Lung metastases alone may be a more sensitive indicator for sorafenib than other organ metastases." @default.
• W1652253116 created "2016-06-24" @default.
• W1652253116 creator A5000292303 @default.
• W1652253116 creator A5014798153 @default.
• W1652253116 creator A5023628852 @default.
• W1652253116 creator A5024948361 @default.
• W1652253116 creator A5040220527 @default.
• W1652253116 creator A5042955462 @default.
• W1652253116 creator A5048295314 @default.
• W1652253116 creator A5048306808 @default.
• W1652253116 creator A5049290580 @default.
• W1652253116 creator A5054412242 @default.
• W1652253116 creator A5054730374 @default.
• W1652253116 creator A5080651363 @default.
• W1652253116 creator A5083281608 @default.
• W1652253116 creator A5091074428 @default.
• W1652253116 date "2015-06-01" @default.
• W1652253116 modified "2023-09-25" @default.
• W1652253116 title "Prognostic analysis of Chinese patients with metastasis renal cell cancer receiving sorafenib: results from a multicenter long-term follow-up retrospective study" @default.
• W1652253116 cites W1547252551 @default.
• W1652253116 cites W1554602088 @default.
• W1652253116 cites W1886991152 @default.
• W1652253116 cites W1990480176 @default.
• W1652253116 cites W1995717891 @default.
• W1652253116 cites W1998499610 @default.
• W1652253116 cites W2006181968 @default.
• W1652253116 cites W2020552064 @default.
• W1652253116 cites W2032265702 @default.
• W1652253116 cites W2035741979 @default.
• W1652253116 cites W2068420541 @default.
• W1652253116 cites W2073363483 @default.
• W1652253116 cites W2084778105 @default.
• W1652253116 cites W2085356529 @default.
• W1652253116 cites W2098119414 @default.
• W1652253116 cites W2099752220 @default.
• W1652253116 cites W2147663823 @default.
• W1652253116 cites W2157262448 @default.
• W1652253116 cites W2158151049 @default.
• W1652253116 cites W2167003072 @default.
• W1652253116 cites W2169961966 @default.
• W1652253116 cites W2170096411 @default.
• W1652253116 cites W2219978888 @default.
• W1652253116 cites W2334803870 @default.
• W1652253116 cites W2400873806 @default.
• W1652253116 doi "https://doi.org/10.2147/ott.s84994" @default.
• W1652253116 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4489821" @default.
• W1652253116 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26170693" @default.
• W1652253116 hasPublicationYear "2015" @default.
• W1652253116 type Work @default.
• W1652253116 sameAs 1652253116 @default.
• W1652253116 citedByCount "4" @default.
• W1652253116 countsByYear W16522531162015 @default.
• W1652253116 countsByYear W16522531162016 @default.
• W1652253116 countsByYear W16522531162017 @default.
• W1652253116 crossrefType "journal-article" @default.
• W1652253116 hasAuthorship W1652253116A5000292303 @default.
• W1652253116 hasAuthorship W1652253116A5014798153 @default.
• W1652253116 hasAuthorship W1652253116A5023628852 @default.
• W1652253116 hasAuthorship W1652253116A5024948361 @default.
• W1652253116 hasAuthorship W1652253116A5040220527 @default.
• W1652253116 hasAuthorship W1652253116A5042955462 @default.
• W1652253116 hasAuthorship W1652253116A5048295314 @default.
• W1652253116 hasAuthorship W1652253116A5048306808 @default.
• W1652253116 hasAuthorship W1652253116A5049290580 @default.
• W1652253116 hasAuthorship W1652253116A5054412242 @default.
• W1652253116 hasAuthorship W1652253116A5054730374 @default.
• W1652253116 hasAuthorship W1652253116A5080651363 @default.
• W1652253116 hasAuthorship W1652253116A5083281608 @default.
• W1652253116 hasAuthorship W1652253116A5091074428 @default.
• W1652253116 hasBestOaLocation W16522531161 @default.
• W1652253116 hasConcept C121608353 @default.
• W1652253116 hasConcept C126322002 @default.
• W1652253116 hasConcept C143998085 @default.
• W1652253116 hasConcept C144301174 @default.
• W1652253116 hasConcept C167135981 @default.
• W1652253116 hasConcept C2776256026 @default.
• W1652253116 hasConcept C2776694085 @default.
• W1652253116 hasConcept C2776907518 @default.
• W1652253116 hasConcept C2777472916 @default.
• W1652253116 hasConcept C2778019345 @default.
• W1652253116 hasConcept C2778695046 @default.
• W1652253116 hasConcept C2779013556 @default.
• W1652253116 hasConcept C2780739268 @default.
• W1652253116 hasConcept C38180746 @default.
• W1652253116 hasConcept C509974204 @default.
• W1652253116 hasConcept C71924100 @default.
• W1652253116 hasConceptScore W1652253116C121608353 @default.
• W1652253116 hasConceptScore W1652253116C126322002 @default.
• W1652253116 hasConceptScore W1652253116C143998085 @default.
• W1652253116 hasConceptScore W1652253116C144301174 @default.
• W1652253116 hasConceptScore W1652253116C167135981 @default.
• W1652253116 hasConceptScore W1652253116C2776256026 @default.
• W1652253116 hasConceptScore W1652253116C2776694085 @default.
• W1652253116 hasConceptScore W1652253116C2776907518 @default.
• W1652253116 hasConceptScore W1652253116C2777472916 @default.
• W1652253116 hasConceptScore W1652253116C2778019345 @default.
• W1652253116 hasConceptScore W1652253116C2778695046 @default.
• W1652253116 hasConceptScore W1652253116C2779013556 @default.

• next